A 12-month, multicenter, randomized, open-label study to investigate efficacy and safety of concentration controlled everolimus with reduced dose Neoral versus mycophenolate mofetil with standard dose Neoral in de novo renal transplant adult recipients treated with basiliximab and corticosteroids.

Trial Profile

A 12-month, multicenter, randomized, open-label study to investigate efficacy and safety of concentration controlled everolimus with reduced dose Neoral versus mycophenolate mofetil with standard dose Neoral in de novo renal transplant adult recipients treated with basiliximab and corticosteroids.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Everolimus (Primary) ; Basiliximab; Ciclosporin; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 27 Sep 2017 Results of 24-month sub-analysis from this trial, presented at the 18th Congress of the European Society for Organ Transplantation.
    • 27 Sep 2017 Results of a subanalysis comparing the efficacy and safety of everolimus+reduced-dose cyclosporine (EVR+rCsA) vs mycophenolate mofetil+standard-dose cyclosporine (MMF+sCsA) regimens in a subpopulation of KTR with ≥3 HLA mismatches, presented at the 18th Congress of the European Society for Organ Transplantation
    • 03 May 2017 Results of subgroup analysis assessing renal function outcome in HLA mismatch groups (n=100) presented at the 2017 American Transplant Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top